Distribution of cisplatin in tumor-free versus tumor-bearing B6D2F1 mice.
In healthy as well as in leukemia P388- or melanoma B16-bearing B6D2F1 mice the platinum concentrations in liver, serum and kidneys were determined after i.v. administration of 10 mg/kg cisplatin. In a tumor stage related to about 40% of the mean survival time (MST) no differences in platinum distribution between tumor-bearing and healthy animals could be observed. In the tumor stage related to about 70% of the MST, elevated platinum levels in serum of both tumor models and in kidneys only in melanoma-bearing but not in leukemia-bearing mice could be found. These results confirm those of other authors that tumor stages less than 50% of the MST exert no marked influence on the distribution pattern of cisplatin in rodents. Moreover, in advanced tumor stages distributional differences of antineoplastic agents may be expected between healthy and tumor-bearing mice as well as between animals bearing different neoplasias.
Amlacher
R
R
Central Institute of Microbiology and Experimental Therapy, Academy of Sciences of the GDR, Jena.
Böckel
V
V
Mackowiak
A
A
Stadeler
M
M
Frankenberg
D
D
Hoffmann
H
H
D000818:Animals; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D007275:Injections, Intravenous; D007941:Leukemia P388 / Q000378:metabolism* / Q000473:pathology; D008546:Melanoma, Experimental / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D012016:Reference Values; D014018:Tissue Distribution
D002945:Cisplatin